Regeneron Pharmaceuticals REGN Other Noncash Income (Expense)
Other Noncash Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's other noncash income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's other noncash income (expense)?
- Regeneron Pharmaceuticals (REGN) reported other noncash income (expense) of -$55.6M in Q1 2026.
- How has Regeneron Pharmaceuticals's other noncash income (expense) changed year-over-year?
- Regeneron Pharmaceuticals's other noncash income (expense) decreased by 1637.5% year-over-year, from -$3.2M to -$55.6M.
- What is the long-term trend for Regeneron Pharmaceuticals's other noncash income (expense)?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's other noncash income (expense) has grown at a -30.1% compound annual growth rate (CAGR), from -$568.7M to -$135.5M.
- What does other noncash income (expense) mean?
- This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.